RT Journal Article
T1 Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
A1 Romero Martínez, Manuel Alejandro
A1 Ramos Alonso, Eva
A1 López-Muñoz, Francisco
A1 Gil-Martín, Emilio
A1 Escames, Germaine
A1 Reiter, Russel J
AB The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.
PB Springer
SN 0272-4340
YR 2022
FD 2022-01
LK https://hdl.handle.net/20.500.14352/120403
UL https://hdl.handle.net/20.500.14352/120403
LA eng
NO Romero, A., Ramos, E., López-Muñoz, F., Gil-Martín, E., Escames, G., & Reiter, R. J. (2022). Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. Cellular and molecular neurobiology, 42(3), 489–500. https://doi.org/10.1007/s10571-020-00938-8
NO Author Contributions Conceptualization, AR; Writing Original Draft Preparation, AR. Writing-Review & Editing, AR, ER, EG-M, FL-M, GE and RJR; Supervision, AR, EG-M and RJR; Funding Acquisition, AR. All authors listed above have approved the fnal version of the manuscript.
DS Docta Complutense
RD 14 jun 2025